

SUPPLEMENTAL ONLINE TABLE

Supplementary Online Table. Summary of patient baseline characteristics for lymphoma cases.

Age/ Sex	Study treatment	Lymphoma diagnosis	Time to lymphoma diagnosis	Duration of RA	No. of swollen (0-66)/tender (0-68) joints	CRP (mg/dL)	DAS28 (0-10) (CRP/ESR) & SDAI (0-100)	Previous medications/ history	EBV status
54 years / F	100 mg	B-cell (follicular) lymphoma	Week 124	8.9 yrs	7 / 15	0.3	5.08/5.90 30.5	MTX, etanercept	ND
60 years / M	Placebo→CO to 50 mg @week 24 →DE to 100 mg @week 64	Large B-cell lymphoma	Week 160	4.7 yrs	29 / 14	1.5	5.35/6.04 41.5	MTX, infliximab, adalimumab	Positive
59 years / F	50 mg→DE to 100 mg @week 100	Diffuse large B-cell lymphoma	Week 124	14.1 yrs	34 / 55	4.8	7.49/8.09 63.6	MTX, etanercept/ Colon cancer	Negative
60 years / F	100 mg	Marginal zone lymphoma	Week 8	31.4 yrs	25 / 17	1.4	6.47/7.56 50.5	DMARDs, etanercept	Negative

CO - crossover, CRP - C-reactive protein, DAS28-CRP - 28-joint-count Disease Activity Score, DE - dose escalation, DMARDs - disease-modifying antirheumatic drugs, EBV - Epstein-Barr virus, F - female, M - male, MTX - methotrexate, ND - not determined, RA - rheumatoid arthritis, SDAI - Simplified Disease Activity Index.